These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 20372833)

  • 1. Prognostic significance of CUB domain containing protein expression in endometrioid adenocarcinoma.
    Mamat S; Ikeda J; Enomoto T; Ueda Y; Rahadiani N; Tian T; Wang Y; Qiu Y; Kimura T; Aozasa K; Morii E
    Oncol Rep; 2010 May; 23(5):1221-7. PubMed ID: 20372833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of CUB domain containing protein (CDCP1) is correlated with prognosis and survival of patients with adenocarcinoma of lung.
    Ikeda J; Oda T; Inoue M; Uekita T; Sakai R; Okumura M; Aozasa K; Morii E
    Cancer Sci; 2009 Mar; 100(3):429-33. PubMed ID: 19077003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of Musashi-1 in endometrioid adenocarcinoma.
    Ma L; Xu YL; Ding WJ; Shao HF; Teng YC
    Int J Clin Exp Pathol; 2015; 8(5):4564-72. PubMed ID: 26191146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.
    Van Gool IC; Stelloo E; Nout RA; Nijman HW; Edmondson RJ; Church DN; MacKay HJ; Leary A; Powell ME; Mileshkin L; Creutzberg CL; Smit VT; Bosse T
    Mod Pathol; 2016 Feb; 29(2):174-81. PubMed ID: 26743472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microarray-based identification of CUB-domain containing protein 1 as a potential prognostic marker in conventional renal cell carcinoma.
    Awakura Y; Nakamura E; Takahashi T; Kotani H; Mikami Y; Kadowaki T; Myoumoto A; Akiyama H; Ito N; Kamoto T; Manabe T; Nobumasa H; Tsujimoto G; Ogawa O
    J Cancer Res Clin Oncol; 2008 Dec; 134(12):1363-9. PubMed ID: 18483744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the CUB domain containing protein 1 (CDCP1) gene in colorectal tumour cells.
    Perry SE; Robinson P; Melcher A; Quirke P; Bühring HJ; Cook GP; Blair GE
    FEBS Lett; 2007 Mar; 581(6):1137-42. PubMed ID: 17335815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Significance of CDCP1 Expression in Colorectal Cancer and Effect of Its Inhibition on Invasion and Migration.
    Chou CT; Li YJ; Chang CC; Yang CN; Li PS; Jeng YM; Chen ST; Kuo ML; Lin IC; Lin BR
    Ann Surg Oncol; 2015 Dec; 22(13):4335-43. PubMed ID: 25820997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas.
    Werner HM; Berg A; Wik E; Birkeland E; Krakstad C; Kusonmano K; Petersen K; Kalland KH; Oyan AM; Akslen LA; Trovik J; Salvesen HB
    Mod Pathol; 2013 Mar; 26(3):428-34. PubMed ID: 23080032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L1 Cell Adhesion Molecule as a Predictor of Disease-Specific Survival and Patterns of Relapse in Endometrial Cancer.
    Pasanen A; Tuomi T; Isola J; Staff S; Bützow R; Loukovaara M
    Int J Gynecol Cancer; 2016 Oct; 26(8):1465-71. PubMed ID: 27648714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CyclinD1, a prominent prognostic marker for endometrial diseases.
    Liang S; Mu K; Wang Y; Zhou Z; Zhang J; Sheng Y; Zhang T
    Diagn Pathol; 2013 Aug; 8():138. PubMed ID: 23947899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. c-Met and RON expression levels in endometrial adenocarcinoma tissue and their relationship with prognosis.
    Zhuang XP; Jin WW; Teng XD; Yuan ZZ; Lin QQ; Xu ST
    Eur J Gynaecol Oncol; 2015; 36(3):255-9. PubMed ID: 26189249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. L1CAM expression in endometrial carcinomas: an ENITEC collaboration study.
    van der Putten LJ; Visser NC; van de Vijver K; Santacana M; Bronsert P; Bulten J; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Trovik J; Kopperud RK; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Jandakova E; Snijders MP; van den Berg-van Erp S; Matias-Guiu X; Salvesen HB; Amant F; Massuger LF; Pijnenborg JM
    Br J Cancer; 2016 Sep; 115(6):716-24. PubMed ID: 27505134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic regulation of the expression of the novel stem cell marker CDCP1 in cancer cells.
    Ikeda JI; Morii E; Kimura H; Tomita Y; Takakuwa T; Hasegawa JI; Kim YK; Miyoshi Y; Noguchi S; Nishida T; Aozasa K
    J Pathol; 2006 Sep; 210(1):75-84. PubMed ID: 16823897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance.
    He Y; Wu AC; Harrington BS; Davies CM; Wallace SJ; Adams MN; Palmer JS; Roche DK; Hollier BG; Westbrook TF; Hamidi H; Konecny GE; Winterhoff B; Chetty NP; Crandon AJ; Oliveira NB; Shannon CM; Tinker AV; Gilks CB; Coward JI; Lumley JW; Perrin LC; Armes JE; Hooper JD
    Oncogene; 2016 Jan; 35(4):468-78. PubMed ID: 25893298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. L1CAM expression associates with poor outcome in endometrioid, but not in clear cell ovarian carcinoma.
    Soovares P; Pasanen A; Bützow R; Lassus H
    Gynecol Oncol; 2017 Sep; 146(3):615-622. PubMed ID: 28625395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CUB domain-containing protein 1, a prognostic factor for human pancreatic cancers, promotes cell migration and extracellular matrix degradation.
    Miyazawa Y; Uekita T; Hiraoka N; Fujii S; Kosuge T; Kanai Y; Nojima Y; Sakai R
    Cancer Res; 2010 Jun; 70(12):5136-46. PubMed ID: 20501830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers.
    Turdo F; Bianchi F; Gasparini P; Sandri M; Sasso M; De Cecco L; Forte L; Casalini P; Aiello P; Sfondrini L; Agresti R; Carcangiu ML; Plantamura I; Sozzi G; Tagliabue E; Campiglio M
    Oncotarget; 2016 Oct; 7(43):69649-69665. PubMed ID: 27626701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship of cerb B 2 expression with estrogen receptor and progesterone receptor and prognostic parameters in endometrial carcinomas.
    Gul AE; Keser SH; Barisik NO; Kandemir NO; Cakir C; Sensu S; Karadayi N
    Diagn Pathol; 2010 Feb; 5():13. PubMed ID: 20167054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyr61, a member of ccn (connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed) family, predicts survival of patients with endometrial cancer of endometrioid subtype.
    Watari H; Xiong Y; Hassan MK; Sakuragi N
    Gynecol Oncol; 2009 Jan; 112(1):229-34. PubMed ID: 19007976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L1CAM as a prognostic marker in stage I endometrial cancer: a validation study.
    Smogeli E; Davidson B; Cvancarova M; Holth A; Katz B; Risberg B; Kristensen G; Lindemann K
    BMC Cancer; 2016 Aug; 16():596. PubMed ID: 27488577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.